Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Effects of APOE4 and education on the clinical onset of autosomal dominant Alzheimer's disease due to the PSEN1 E280A mutation
Aging, Dementia, and Behavioral Neurology
S39 - Neurobiology of Dementia (4:06 PM-4:18 PM)
004

Autosomal dominant Alzheimer’s disease (ADAD) is genetically determined, but variability in age of symptom onset suggests it may be influenced by additional genetic and environmental risk factors. Although the e4 allele of the apolipoprotein E (APOE4) gene and education level both influence clinical onset of dementia in sporadic Alzheimer’s disease (AD), it is unclear whether APOE4 affects onset of ADAD. Here, we investigated the effects of APOE4 and education on the clinical onset of ADAD.

Determine the impact of APOE4 genotype and education on the clinical onset of autosomal dominant Alzheimer’s  disease.

We analyzed retrospective data from 675 presenilin-1 (PSEN1) E280A mutation carriers (141 APOE4 carriers, 534 APOE4 non-carriers) and 594 PSEN1 non-carriers (148 APOE4 carriers, 446 APOE4 non-carriers) from a Colombian kindred with ADAD. We used the Mini-Mental State Examination (MMSE) as a proxy for clinical impairment. Model parameters in both PSEN1 carriers and non-carriers were estimated using a Hamiltonian Markov chain Monte Carlo method. The age-related trajectories of APOE4 carriers versus non-carriers were compared in both PSEN1 carriers and non-carriers.

In PSEN1 carriers, lower MMSE scores began to significantly differentiate APOE4 carriers from non-carriers at age 45, the average age of mild cognitive impairment onset in this kindred. Years of education moderated the effect of APOE such that APOE4 carriers with lower educational levels had lower average MMSE scores in comparison to APOE4 non-carriers.

Our findings suggest 1) age-related changes in global cognitive function may be accelerated in ADAD mutation carriers who are APOE4 carriers, compared to APOE4 non-carriers; and 2) higher educational levels may have a protective effect against cognitive impairment, even in the presence of genetic risk factors. Further longitudinal studies are necessary to clarify the impact of both education and APOE4 genotype on ADAD clinical progression.

Authors/Disclosures
Nicholas G. Barksdale, BA
PRESENTER
Mr. Barksdale has nothing to disclose.
No disclosure on file
No disclosure on file
David F. Aguillon, Sr. (Universidad de Antioquia) No disclosure on file
No disclosure on file
No disclosure on file
No disclosure on file
No disclosure on file
No disclosure on file
No disclosure on file
No disclosure on file
No disclosure on file
No disclosure on file
No disclosure on file
Silvia J. Rios Romenets, MD Dr. Rios Romenets has nothing to disclose.
No disclosure on file
Hyun-Sik Yang, MD (Brigham and Women'S Hospital) The institution of Dr. Yang has received research support from National Institutes of Health. Dr. Yang has received personal compensation in the range of $500-$4,999 for serving as a study section member with National Institutes of Health.
No disclosure on file
Jeremy J. Pruzin, MD (Banner Alzheimer's Institute) Dr. Pruzin has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eisai. Dr. Pruzin has received personal compensation in the range of $500-$4,999 for serving as a Consultant for MedNet. Dr. Pruzin has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Synapticure. The institution of Dr. Pruzin has received research support from Alzheimer's Association. The institution of Dr. Pruzin has received research support from NIA.
No disclosure on file
No disclosure on file
Kenneth S. Kosik, MD Dr. Kosik has received personal compensation in the range of $50,000-$99,999 for serving as an officer or member of the Board of Directors for Rainwater Foundation. The institution of Dr. Kosik has received research support from National Institute of Health. The institution of Dr. Kosik has received research support from Hillblom Foundation. The institution of Dr. Kosik has received research support from Adelson Medical Foundation. The institution of Dr. Kosik has received research support from Alzheimer Association/Rainwater Foundation. The institution of Dr. Kosik has received research support from Thome Memorial FOundation.
Eric M. Reiman, MD (Banner Alzheimer's Institute) Dr. Reiman has received personal compensation in the range of $50,000-$99,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Denali, Green Valley, Zinfandel, and Takeda. Dr. Reiman has received stock or an ownership interest from Alkahest, Alzheon, Aural Analytics, Denali, and United Neuroscience.. Dr. Reiman has received intellectual property interests from a discovery or technology relating to health care. Dr. Reiman has received personal compensation in the range of $500-$4,999 for serving as a Member, National Advisory Council on Aging (NACA) with NIA.
Francisco J. Lopera Restrepo, MD, PhD (Universidad De Antioquia) No disclosure on file
Yakeel Quiroz, PhD Dr. Quiroz has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Dr. Quiroz has received intellectual property interests from a discovery or technology relating to health care.